29 results
8-K
EX-1.1
TCRX
Tscan Therapeutics Inc
17 Apr 24
TScan Therapeutics Announces Launch of $125 million Proposed
6:25am
expenses incident to the performance of its obligations under this Agreement, including: (i) the fees, disbursements and expenses of the Company’s … to subsections (iii) and (iv) shall not exceed $30,000 in the aggregate), (v) all costs and expenses incident to listing the Securities on the NASDAQ Global
8-K
EX-99.2
TCRX
Tscan Therapeutics Inc
16 Apr 24
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
4:16pm
volume (mm ) IL-2 (pg/mL)
Programs address targets frequently co-expressed in prevalent solid tumors Head & Neck Melanoma 66 K Incident Patients … in U.S. 100 K Incident Patients in U.S. 100 90 100 90 80 80 50 50 50 60 60 45 40 40 40 25 25 20 20 0 0 0 HPV16 MAGE-C2 MAGE-A4 PRAME MAGE-A1 HPV16 MAGE-C2
8-K
EX-1.1
14fo2ypsr347h7w
31 May 23
TScan Therapeutics Announces Launch of Proposed Public Offering
8:16am
8-K
EX-1.1
ui2o5uj
16 May 23
Other Events
5:21pm
8-K
EX-10.1
s63g9hp
12 Sep 22
TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures
7:51am
10-K
bqr2t4xv6x4dp
9 Mar 22
Annual report
7:30am
10-Q
l3qu8nh nmhooogx
19 Aug 21
Quarterly report
7:31am
8-K
EX-3.2
533p364 j6sv3wzlz84w
20 Jul 21
Departure of Directors or Certain Officers
4:36pm
424B4
i42mwo4ujxh7 149ft
19 Jul 21
Prospectus supplement with pricing info
7:01am